Everything below concerns pentapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-04. Numbers and descriptions here follow the published literature rather than marketing material.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
=== Allergy === HLA-G has links to allergenic responses in the body. Soluble HLA-G levels are higher in the serum of people with allergic rhinitis, or hay fever. Additionally, single nucleotide polymorphisms in HLA-G have been connected to an increased likelihood of having asthma. Papillary cells expressing HLA-G were found in patients with atopic dermatitis.
They were treated for about four years and gained 4-8 cm in adult height. Controversy has arisen as to whether all of these children were truly "short normal" children, since the average IGF1 was low. Approval of HGH for the treatment of this extreme degree of shortness led to an increase in the number of parents seeking its use to make otherwise normal children a little taller.
Stark writes that the "characteristics of the earliest members of a movement will tend to be reproduced in subsequent converts." A significant percentage of Scientists remained single (Eddy placed little emphasis on marriage and family), or became Scientists when their children were adults and unlikely to be converted. Christian Science did not have missionaries, so it relied on internal growth, but the conversion rate within families was not high. In a study cited by Stark, of 80 people raised within Christian Science just 26 (33 percent) became Scientists themselves.
==== Traumatic calcinosis cutis ==== Traumatic calcinosis cutis is a cutaneous condition characterized by calcification of the skin resulting from the deposition of calcium and phosphorus often resulting from occupational exposure, as in cases reported in oil-field workers and coal miners.
==== Splenic sequestration crisis ==== The spleen is prone to damage in sickle cell disease due to its role as a blood filter. A splenic sequestration crisis, also known as a spleen crisis, is a medical emergency that occurs when sickled red blood cells block the spleen's filter mechanism, causing the spleen to swell and fill with blood. The accumulation of red blood cells in the spleen results in a sudden drop in circulating haemoglobin and potentially life-threatening anaemia. Symptoms include left-sided pain, swollen spleen (which can be detected by palpation), fatigue, dizziness, irritability, rapid heartbeat, or pale skin. It most commonly affects young children; the median age of first occurrence is 1.4 years. By the age of 5 years, repeated instances of sequestration cause scarring and eventual atrophy of the spleen. Treatment is supportive, with blood transfusion if haemoglobin levels fall too low. Full or partial splenectomy may be necessary. Long-term consequences of a loss of spleen function are increased susceptibility to bacterial infections.
Sources: en.wikipedia.org
=== Advanced tools === By around 200,000 BP, Middle Paleolithic stone tool manufacturing spawned a tool-making technique known as the prepared-core technique, which was more elaborate than previous Acheulean techniques. This technique increased efficiency by allowing the creation of more controlled and consistent flakes. It allowed Middle Paleolithic humans to create stone-tipped spears, which were the earliest composite tools, by hafting sharp pointy stone flakes onto wooden shafts. In addition to improving tool-making methods, the Middle Paleolithic also saw an improvement of the tools themselves that allowed access to a wider variety and amount of food sources. For example, microliths or small stone tools or points were invented around 70,000–65,000 BP and were essential to the invention of bows and atlatls (spear throwers) in the following Upper Paleolithic. Harpoons were invented and used for the first time during the late Middle Paleolithic (c. 90,000 BP); the invention of these devices brought fish into the human diets, which provided a hedge against starvation and a more abundant food supply. Thanks to their technology and their advanced social structures, Paleolithic groups such as the Neanderthals—who had a Middle Paleolithic level of technology—appear to have hunted large game just as well as Upper Paleolithic modern humans, and the Neanderthals in particular may have likewise hunted with projectile weapons.
Information technology, particularly optical fiber and optical amplifiers, allowed for simple and fast long-distance communication, which ushered in the Information Age and the birth of the Internet. The Space Age began with the launch of Sputnik 1 in 1957, and later the launch of crewed missions to the moon in the 1960s. Organized efforts to search for extraterrestrial intelligence have used radio telescopes to detect signs of technology use, or technosignatures, given off by alien civilizations. In medicine, new technologies were developed for diagnosis (CT, PET, and MRI scanning), treatment (like the dialysis machine, defibrillator, pacemaker, and a wide array of new pharmaceutical drugs), and research (like interferon cloning and DNA microarrays). Complex manufacturing and construction techniques and organizations are needed to make and maintain more modern technologies, and entire industries have arisen to develop succeeding generations of increasingly more complex tools. Modern technology increasingly relies on training and education – their designers, builders, maintainers, and users often require sophisticated general and specific training. Moreover, these technologies have become so complex that entire fields have developed to support them, including engineering, medicine, and computer science; and other fields have become more complex, such as construction, transportation, and architecture.
=== In Mount Lebanon === The "Druze-Christian alliance" during the Emirate of Mount Lebanon, from the mid-16th to the early-19th century, and the "Maronite-Druze dualism" in Mount Lebanon Mutasarrifate from the 19th to the 20th centuries, laid the foundation for what is now Lebanon. This is celebrated as establishing a kind of Druze-Maronite condominium, often depicted as the precursor of Lebanese statehood and Lebanese national identity. While Lebanese nationalism appeals to the Lebanese Maronite and Druze communities, it is generally unpopular among Lebanese Muslims, who often support Pan-Arabism and Pan-Islamism, as well as among Greek Orthodox Christians. Druze author Yusuf Khatat Abu Shaqra, in his book Movements in Lebanon, stated: "In the past, there was no discord or estrangement between the Druze and Christians in Lebanon, as there has been since the year 1800. Instead, the two communities had affection for one another, were friendly, and, in other words, operated as one group, working together in harmony".
Official website Food and Drug Administration in the Federal Register Food and Drug Administration in the Code of Federal Regulations Strategic Plan (archived) Works by Food and Drug Administration at Open Library Online books by United States Food and Drug Administration at The Online Books Page Food and Drug Administration apportionments on OpenOMB
== External links == "Carol Robinson's Interview with Denis Noble". YouTube. voicesfromoxfordUK. 18 December 2013. (See Denis Noble.) "A New Phase for Structural Biology – with Carol Robinson". YouTube. The Royal Institution. 6 July 2016. "Mass spectrometry: From ribosomes to receptors | Prof Dame Carol Robinson DBE FRS FMedSci". YouTube. Cambridge SciSoc. 26 March 2021. "Carol Vivien, DBE, FRS, FMedSci ~ 10/14/2020 – Physiology Bashour Speaker". YouTube. UTSW Department of Physiology. 29 March 2021. "JACS in Conversation with Professor Dame V. Robinson". YouTube. ACS Productions. 7 September 2021. (interview conducted by Erick M. Carreira)
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.